Peptídeos, promovidos como antienvelhecimento e para performance, carecem de comprovação científica e aprovação regulatória no Brasil. Especialistas alertam para riscos de uso sem orientação médica.
A EMS lançou sua caneta de semaglutida, Ozivy, nas farmácias brasileiras. O medicamento, primeiro nacional após a queda da patente, tem preço inicial de R$ 452 e visa controlar o nível de açúcar no sangue.
O reposicionamento de medicamentos, que consiste em encontrar novos usos para fármacos já existentes, tem se mostrado uma estratégia eficaz e econômica para salvar vidas, especialmente em crises de saúde como a da COVID-19. Medicamentos como a dexametasona e o baricitinibe foram reaproveitados para tratar a inflamação em pacientes com coronavírus, salvando milhares de vidas. A Comissão Europeia planeja expandir essa abordagem para a busca de tratamentos contra o câncer. Exemplos históricos incluem o raloxifeno para prevenção de câncer de mama, a talidomida para mieloma múltiplo e o Viagra (sildenafil) para disfunção erétil, originalmente desenvolvido para doenças cardiovasculares. A tendência de reaproveitamento de medicamentos levanta questões sobre seus verdadeiros prós e contras, cujas respostas podem levar anos para serem totalmente compreendidas.
Novas diretrizes médicas nos EUA e Brasil priorizam semaglutida e tirzepatida para obesidade, com foco em mudanças de estilo de vida. Documentos organizam drogas por hierarquia e risco cardiovascular, visando melhorar saúde e reduzir mortalidade.
The UK's MHRA has approved the first GLP-1 receptor agonist tablet, semaglutide (Wegovy), for weight loss and management. This daily pill offers a more convenient alternative to weekly injections for adults with obesity or those overweight with weight-related conditions.
Boehringer Ingelheim's experimental drug, survodutide, has shown significant potential in reducing liver fat accumulation, a condition known as MASLD/MASH. Presented at the American Diabetes Association (ADA) annual meeting, the drug targets both weight loss and metabolic health, offering a new approach beyond traditional obesity treatments.
A study by the University of California, San Diego, suggests semaglutide, a drug for weight loss and diabetes, may slow biological aging. Participants taking semaglutide showed a 9% reduction in aging rate and improved health markers compared to a placebo group.
A new analysis shows semaglutide (Ozempic/Wegovy) slows kidney disease progression in type 2 diabetes patients, improving kidney function and survival rates, even with a history of cardiovascular events. The drug mimics GLP-1 hormones and is also popular for weight loss.
Medicamento para obesidade, semaglutida, chega ao Brasil com preço acessível. Versão nacional da EMS custará R$ 287 por mês na fase inicial, bem abaixo dos R$ 1 mil mensais anteriores.
Alkem Laboratories launched semaglutide in single-shot pre-filled syringes in India, making diabetes and obesity treatment more accessible and affordable. The company is the first in India to offer this format, intensifying competition in the growing drug market.
A UK study suggests Semaglutide may benefit patients unresponsive to bariatric surgery. Separately, oats are highlighted for their role in managing blood sugar for diabetics due to soluble fiber. Additionally, experts warn that processed foods, refined carbs, and high sodium/saturated fat diets can exacerbate stress hormone (cortisol) levels.
Scientists found that semaglutide and colchicine protect heart tissue from inflammation and electrical signaling disturbances that can cause arrhythmias. Semaglutide notably reduces scar tissue in the atria and maintains normal electrical impulse transmission.
Prices for generic semaglutide, a weight-loss drug, may drop by over 50% in 6-8 months due to new market entrants and reduced API costs, potentially reaching ₹500/month.
New generics in Canada likely mark the start of a decline in international revenue of semaglutide, the active ingredient in Novo's Ozempic and Wegovy.
Dr Reddy's Laboratories has become the first company to receive Health Canada approval for generic semaglutide injection, covering 2 mg/pen and 4 mg/pen dosages. The approval, granted ahead of the regulatory review target date, marks a significant milestone in the company's GLP-1 journey and aims to expand access to affordable diabetes treatments for Canadian patients, where approximately 3.9 million people (9.7% of the population) live with diagnosed diabetes.
Dr Reddy's Laboratories has received notice of compliance from Health Canada for its generic semaglutide injection, becoming the first company to receive market authorization for this diabetes treatment in Canada. The approval covers 2 mg/pen and 4 mg/pen dosages. The company is preparing to launch the medication to provide Canadian patients with access to this therapy.
